Articles tagged with Type 1 Diabetes
Dr. Wenbo Zhi, a postdoctoral fellow at the Medical College of Georgia, has received a two-year fellowship to study biomarkers associated with type 1 diabetes. He aims to identify protein biomarkers that can improve diagnosis and treatment using proteomic techniques.
Researchers aim to teach the immune system to ignore insulin-producing cells by boosting IDO levels. By enhancing this natural mechanism, they hope to slow or prevent disease progression in high-risk children. A new treatment approach could provide a breakthrough in preventing type 1 diabetes.
Researchers describe a potential new therapeutic approach for diabetic retinopathy using ASP-440, a protease plasma kallikrein inhibitor. The study showed significant reductions in retinal vascular permeability and blood pressure in rodents, suggesting promising results for treating the condition.
JDRF-funded researchers at the University of Pittsburgh School of Medicine discovered a protein called cdk6 that regulates human beta cell replication. This finding provides proof-of-principle for stimulating human beta cell production and function.
A new study published in Value in Health estimates that Americans with diabetes had nearly 22% of hospital charges in 2005, totaling $171 billion. The study also found that individuals with type 1 diabetes were more likely to be hospitalized than those with type 2 diabetes.
Researchers at Albert Einstein College of Medicine developed a technique to make foreign pancreatic cells invisible to the immune system, dramatically protecting them from rejection. The new method could pave the way for routine use of cell transplants as a therapy for type 1 diabetes in humans.
A study from the Norwegian Institute of Public Health found no significant link between human parechovirus infections and typical symptoms in infants. However, researchers noticed an increase in parechovirus infection between 6-18 months, which could be due to factors such as maternal antibody loss or nursery exposure.
A study by researchers at Joslin Diabetes Center found that nearly three-quarters of youths with type 1 diabetes have insufficient levels of vitamin D, which may lead to bone fragility and increased fracture risk. The study recommends vitamin D supplementation to children with diabetes, especially those with inadequate sun exposure and...
Type 1 diabetes and celiac disease share common genetic mechanisms, including autoimmunity-related tissue damage and intolerance to dietary antigens, the study found. Researchers identified seven chromosome regions shared between the two diseases, suggesting a potential link in environmental triggers as well.
A recent study published in Diabetes Care highlights the significant barriers faced by type 1 diabetics when it comes to engaging in physical activity. The researchers found that those with a greater fear of hypoglycemia were also more likely to have poorer diabetes control, emphasizing the need for targeted education and support.
Researchers at UCSF used kinase inhibitors to block and reverse type 1 diabetes in mice, showing potential for new therapeutic approach. The study found that 80% of mice with established diabetes reversed symptoms after two months of treatment.
Researchers found that cancer drugs imatinib and sunitinib can put type 1 diabetes into remission in 80% of test mice. The benefits of the drugs' rapid action are attributed to their ability to block platelet-derived growth factor receptor, a tyrosine kinase not known to be implicated in diabetes.
A population-based study of Type 1 diabetes patients found that better glycemic control reduces diabetic retinopathy progression. Additionally, a cohort study on age-related macular degeneration (AMD) discovered an association between poor night vision and increased risk of AMD progression.
A DNA vaccine, BHT-3021, is being developed to reverse the immune response causing type 1 diabetes. The vaccine has shown safety and preliminary data indicate it may preserve beta cells and induce immune tolerance.
Researchers found that green tea's EGCG reduced salivary gland damage and delayed insulin-dependent type 1 diabetes in a laboratory mouse. The study also showed that EGCG suppressed abnormal gene expression and lowered serum autoantibodies, reducing Sjogren's syndrome-like symptoms.
SmartCells' SmartInsulin is a once-a-day, glucose-regulated insulin that maintains continuous blood glucose control while reducing hypoglycemia risk. JDRF's $1M funding supports preclinical safety and efficacy testing for this treatment, aiming to improve patient safety and quality of life.
Dr. Xingxing Zang receives Type 1 Diabetes Pathfinder Award for his innovative research on B7x protein, which may prevent T lymphocytes from destroying pancreatic cells. The award supports his five-year study to explore the role of B7x in diabetes prevention and treatment.
Researchers have identified two novel gene locations associated with an increased risk of developing type 1 diabetes. The study, published in Diabetes, provides a promising lead for the development of more accurate diagnostic tests and potential preventive therapies.
Researchers at Beth Israel Deaconess Medical Center discovered that the AAT protein can restore normal blood glucose levels in a mouse model of Type 1 diabetes. The study suggests that inflammation plays a key role in the disease and provides evidence for using the protein as an alternative treatment option.
A JDRF-funded study suggests that exposure to certain bacteria may provide protection against developing type 1 diabetes. Researchers found that mice exposed to these harmless microbes had a lower risk of autoimmune disorders. The findings lend support to the 'hygiene hypothesis' and may lead to new therapeutic approaches for prevention.
The DIRECT studies found that candesartan can reduce the incidence of retinopathy in type 1 diabetes and increase its regression in type 2 diabetes. The treatment also showed a significant reduction in risk of progression by three or more steps on the EDTRS scale.
Researchers at Yale University and the University of Chicago showed that mice exposed to common stomach bacteria were protected against Type I diabetes. The findings support the so-called
A study by Stanford University scientists reveals that type 1 diabetes may not be caused by bad genes but by how normal genes and gene variants are expressed. Researchers found differences in gene expression between two groups of mice, suggesting a role for environmental stimuli in triggering the disease.
A multicenter clinical trial funded by the Juvenile Diabetes Research Foundation found that continuous glucose monitoring significantly improved blood sugar control in patients with type 1 diabetes. HbA1c levels decreased by an average of 0.53% in patients aged 25 and older, while improvements were not observed in younger age groups.
Researchers at MGH confirmed a potential new therapy for type 1 diabetes by selectively killing autoimmune cells in human patients. The treatment, which blocks a metabolic pathway regulating the immune system, eliminates immune cells that react against a patient's own tissues.
Researchers found that leptin can lower blood glucose levels and maintain them in a normal range for extended periods. The study shows promise for treating type 1 diabetes without insulin injections.
The JDRF Scholar Award is granted to individual scientists who exhibit a unique creative vision and approach to research. Dr. Jeffrey Bluestone and Dr. Mark Cooper are the recipients of this prestigious award, which provides them with $250,000 annually for up to five years to conduct specialized research.
The University of South Florida has been awarded a seven-year, $128 million NIH grant to coordinate worldwide studies on the prevention and treatment of juvenile diabetes. The TrialNet project will screen over 150,000 children and adults to investigate new therapies for early signs of diabetes.
Researchers at Broad Institute will explore ways to regenerate human cells lost in type 1 diabetes, using chemical biology and genomic tools. The goal is to find ways to replenish missing cells, potentially reducing or eliminating lifelong insulin therapy.
Researchers at UIC are testing new approaches to islet transplantation to improve insulin independence and glucose control for adults with difficult-to-control type 1 diabetes. The study aims to find the most effective combination of anti-rejection drugs to maximize islet engraftment and reduce toxic side effects.
A study at the Joslin Diabetes Center found that children with type 1 diabetes who closely adhered to prescribed dietary recommendations had lower A1C levels and reduced risk of diabetes-related complications. The study highlights the importance of dietary adherence in achieving optimal glucose control.
A team of Florida scientists, including Mark Atkinson, Michael Haller, and Desmond Schatz, have received the sixth annual Excellence in Clinical Research Award from JDRF International. The award recognizes their innovative work on using umbilical cord blood stem cells and drug treatments to prevent and reverse type 1 diabetes.
The TRAF1/C5 gene locus is associated with both type 1 diabetes and systemic lupus erythematosus, with a common odds ratio of 1.19 and 1.22 respectively indicating a modest genetic risk factor for these diseases. The study suggests that this genetic pathway may be shared across autoimmune disorders.
A unique drug combination, Lisofylline and Islet Neogenesis Associated Protein peptide, has shown promising results in reversing Type 1 diabetes in diabetic mice. The study found that the combination led to a remission rate of 70% in mice with high blood glucose levels.
Researchers found that patients who gained weight over time had lower mortality rates, suggesting that a reasonable amount of weight gain may be a sign of adequate insulin control. The study also found no significant difference in mortality between those with an overweight or normal BMI and those with an underweight BMI.
A recent study by Moores UCSD Cancer Center researchers found that populations living near the equator have lower incidence rates of type 1 diabetes, suggesting a strong role for vitamin D in reducing disease risks. The study's findings support the concept of using vitamin D to prevent childhood type 1 diabetes.
A new vaccine approach using microspheres has prevented and reversed new-onset cases of type 1 diabetes in animal models. The microspheres, developed by the Children's Hospital of Pittsburgh, reprogram dendritic cells to block the immune system's attack on insulin-producing beta cells.
Type 1 diabetes incidence among Finnish children more than doubled from 1980-2005, with a significant increase in obesity and early weight gain implicated as risk factors. The predicted cumulative number of new cases between 2006-2020 is around 10800, highlighting the need for urgent action to address environmental triggers.
Researchers at Washington University School of Medicine have identified dendritic cells carrying insulin fragments as a key player in the development of type 1 diabetes. The discovery sheds light on how an immune system attack can destroy the islets of Langerhans, leading to insulin deficiency and the disease.
The READ-2 study, a collaboration between JDRF, Johns Hopkins, and Genentech, found that ranibizumab injections significantly improved visual acuity and reduced excess retinal thickness in patients with diabetic macular edema. The treatment resulted in a 56% reduction in retinal thickness compared to laser photocoagulation therapy.
A Kaiser Permanente study found that diabetes more than doubled in six years among teenage and adult women before becoming pregnant. The largest study to date examined 175,000 teenage girls and adult women, revealing significant jumps in pre-pregnancy diabetes in every age, racial, and ethnic group.
Researchers found that people with diabetes have the same high risk for heart attack or stroke as those who've already had a heart attack. The study suggests that all patients with diabetes receiving glucose-lowering treatment are at a particularly high risk of cardiovascular death and disease, regardless of sex and diabetes type.
Scientists at MGH are exploring a potential cure for type 1 diabetes through a Phase I clinical trial. The trial uses the BCG vaccine, which has shown promising results in mouse models of autoimmune diabetes.
A systematic review and meta-analysis found that vitamin D supplements in early childhood lower the risk of developing type 1 diabetes by around 30%. Higher doses and more regular supplementation were associated with a greater reduction in risk.
A new study by Joslin Diabetes Center found that restricting insulin doses in women with type 1 diabetes is associated with a three-fold increased risk of death and higher rates of disease complications. The study also highlighted the connection between insulin restriction and eating disorder symptoms, often referred to as diabulimia.
Researchers are exploring the potential of generating insulin-producing cells using adult stem cells to treat type 1 diabetes. The partnership aims to restore normal blood sugar levels through autologous cell transplantation, eliminating the need for immunosuppressive agents.
The JDRF Autoimmunity Center will focus on developing novel antigen-specific approaches to predict, prevent, and possibly reverse type 1 diabetes. The center will utilize the Barbara Davis Center's resources in collaboration with JDRF to create therapies specifically aimed at immunoprevention of type 1 diabetes.
A recent study suggests that impaired CD4+Treg cells may contribute to the development of type 1 diabetes. Dr. Ciriaco Piccirillo's research indicates that these cells' regulatory function is compromised in patients with type 1 diabetes, allowing misprogrammed T lymphocytes to attack insulin-producing cells.
Professor Jens Høiriis Nielsen from the University of Copenhagen receives a JDRF research grant to investigate beta cell expansion during pregnancy. The goal is to discover new approaches for treating type 1 diabetes, potentially leading to regenerative drugs and therapies.
Researchers at UC Davis Health System have identified a novel pathway that contributes to increased inflammation of blood vessels in type 1 diabetes patients. This finding may lead to the development of new treatments to reduce cardiovascular disease risk by controlling inflammation.
Researchers at the University of Virginia Health System have identified a key enzyme involved in the development of Type 1 diabetes. The discovery, centered on the 12/15-lipoxygenase gene, has significant implications for understanding and treating the disease, with potential applications for preventing or reversing Type 1 diabetes.
The UMass Chan Medical School Heat Shock Protein Consortium will investigate the causes of type 1 diabetes with dual grants from the Juvenile Diabetes Research Foundation (JDRF) and The Iacocca Foundation. The research aims to understand the role of cellular stress in autoimmune diabetes, with specific focus on endoplasmic reticulum st...
Researchers at UMass Medical School will study the role of heat shock proteins in type 1 diabetes using dual grants from JDRF and the Iacocca Foundation. The $300,000 funding supports innovative studies across various departments and disciplines to understand Hsp abnormalities that may lead to type 1 diabetes.
EpiVax receives $351,000 from JDRF to develop Epi-13, a novel therapeutic that reduces harmful immune responses and preserves insulin production. The approach uses natural regulatory T cells to induce antigen-specific adaptive tolerance induction.
JDRF is partnering with Osiris Therapeutics to support a Phase II clinical trial using Prochymal, an immunomodulatory cell therapy product, to preserve and regenerate insulin-producing cells in patients newly diagnosed with type 1 diabetes. The proposed research presents a novel approach for developing a immunomodulatory cellular therapy.
The Juvenile Diabetes Research Foundation (JDRF) has partnered with Housey Pharmaceutical Research Laboratories to develop small molecule compounds promoting beta cell growth and survival. This research aims to identify new therapeutics targeting key scientific pathways, accelerating drug discovery and development.
A study found that children with a high genetic risk of developing type 1 diabetes who consumed more omega-3 fatty acids had a reduced risk of pancreatic islet autoimmunity, which is linked to the disease. The researchers concluded that higher total omega-3 fatty acid intake was associated with a lower risk of IA.
A new triple combination therapy has been successful in abolishing adverse autoimmunity against insulin-producing cells in a mouse model of Type 1 diabetes. The treatment eliminated inflammation and restored normal blood glucose levels by blocking its effects on fat and muscle tissues.
Researchers have identified a new gene, KIAA0350, associated with an increased risk of type 1 diabetes in children. The study used genome-wide association to analyze DNA samples from 1,046 children with the disease and found a significant link between a specific genetic variant and the development of type 1 diabetes.
Researchers found that cord blood infusions significantly reduced insulin requirements and improved blood sugar control in children with type 1 diabetes. The treatment also increased regulatory immune cells, suggesting potential immunotherapy benefits.